ClinicalTrials.gg
WithdrawnNCT04537975Updated Dec 14, 2020

C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19

An interventional study of C2Rx and Standard of Care (SOC) in Continuous Renal Replacement Therapy, Pulmonary Edema and COVID-19, sponsored by SeaStar Medical. Withdrawn. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-12-14.

Sponsored by SeaStar Medical · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Withdrawn (Study was withdrawn by Sponsor because of change in regulatory strategy.)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The clinical trial will evaluate the short term and extended impact on on respiration, pulmonary function and cardiovascular function in C2Rx treatment verse Standard of Care (SOC) in critically ill adults with COVID-19 infections .

02

Conditions studied

  • Continuous Renal Replacement Therapy
  • Pulmonary Edema
  • COVID-19
03

In context

Pulmonary Edema

127 studies on the registry are indexed under Pulmonary Edema; 28 are open to participants now.

Browse Pulmonary Edema studies →

Lead sponsor

SeaStar Medical is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A patient, or legal authorized representative (LAR), has provided and a written informed consent form.
  • Positive COVID-19 test.
  • Must be receiving medical care in an intensive care nursing situation.
  • Respiratory failure due to COVID-19 disease requiring invasive mechanical ventilation. This care may include but is not required to include the use of dexamethasone.
  • Within 18 hours of tracheal intubation to support invasive mechanical ventilation. A goal of this study is that T0 will occur within 24 hours of tracheal intubation to support invasive mechanical ventilation.
  • Age 18 to 80 years.
  • Males and females (females of who are not pregnant confirmed by a negative serum pregnancy test) and not lactating if recently post-partum).
  • Intent to deliver full supportive care through aggressive management utilizing all available therapies for a minimum of 96 hours.

Exclusion criteria

Exclusion Criteria:

  • Cardiovascular instability that precludes initiation of hemofiltration.
  • Irreversible brain damage based on available historical and clinical information.
  • Presence of any solid organ transplant at any time.
  • Patients with stem cell transplant in the previous 100 days or who have not engrafted.
  • Acute or chronic use of circulatory support device such as extracorporeal membrane oxygenation (ECMO), left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), biventricular assist devices (BIVADs).
  • which is actively being treated or may be treated with chemotherapy or radiation during the subsequent three-month period after study treatment.
  • Chronic defined as use of any immunosuppressant medications (cyclophosphamide, azathioprine, methotrexate, rituximab, mycophenolate, cyclosporine); prednisone use is excepted.
  • Patient is moribund or chronically debilitated for whom full supportive care is not indicated.
  • Concurrent enrollment in another interventional clinical trial except trials of COVID-19 convalescent plasma, anti-severe acute respiratory syndrome (SARS)-CoV2 monoclonal antibodies, or RemdesivirTM. Patients enrolled in observational studies (without the use of an investigative device or drug), are allowed to participate. Any communication between the Principal Investigator (PI) of this Protocol and the PI of any other clinical study will include the Medical Director of the Sponsor; all such correspondence will be documented.
  • Any reason the Investigator deems exclusionary
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    C2Rx

    Hemofiltration device

    Device: C2Rx

  • Active comparator
    Standard of Care (SOC)

    Standard of Care based on protocol inclusion/exclusion criteria

    Other: Standard of Care (SOC)

Interventions

  • DeviceC2Rx

    Hemofiltration

  • OtherStandard of Care (SOC)

    Standard of care that excludes any protocol restrictions.

06

What researchers measure

Primary outcomes

  1. Pulmonary Oxygenation Function

    Change in patient Arterial Oxygen Partial Pressure (PaO2)/Fractional Inspired Oxygen (FiO2) Ratio

    Time frame: Up to 72 hours

Secondary outcomes

  1. Pulmonary Compliance of Respiratory System (CRS)

    Change in patient oxygenation

    Time frame: Up to 96 hours

  2. Survival

    Change in the total number of patients that survived

    Time frame: 30 days and 60 days

  3. Hospital Costs 1

    Change in Hospital Utilization of ventilators (days)

    Time frame: Out to 60 days

  4. Cardiovascular Vasoactive-Inotropic Score (VIS)

    Change in score based on the calculation of the following medications used: dopamine dose (µg/kg/min) + dobutamine dose (µg/kg/min) + 100 x adrenaline dose (µg/kg/min) + 100 x noradrenaline dose (µg/kg/min) + 10 x milrinone dose (µg/kg/min) + 10.000 x vasopressin dose (U/kg/min)

    Time frame: Up to 96 hours

  5. Hospital Costs 2

    Change in Hospital Utilization of vasopressor medication (days without use)

    Time frame: Out to 60 days

  6. Hospital Costs 3

    Change in Hospital Utilization of Intensive Care Unit (ICU) Hospital free days

    Time frame: Out to 60 days

  7. Hospital Costs 4

    Change in Hospital Utilization of Renal Replacement Therapy (days on therapy)

    Time frame: Out to 60 days

  8. Hospital Costs 5

    Change in Hospital Utilization (days hospitalized)

    Time frame: Out to 60 days

Other outcomes

  1. Inflammatory mediators in blood

    Changes in inflammatory mediators detected by Immunoassay of Multianalyte Panel - MAP Laboratory Panel of 253 analytes.

    Time frame: Out to 14 hours

  2. Cytokine Sieving Effects

    Change in cytokine levels obtained from plasma and blood collected prior to and after filter. Analyte concentrations in ultrafiltrate and plasma, expressed in the same concentration units, will be aggregated as a ratio of ultrafiltrate concentration to plasma concentration to yield a unitless Sieving Coefficient (SC). SC is an index of membrane function.

    Time frame: Out to 8 hours

  3. Specific Blood Indicators 1

    Change in blood Ferritin (mg/mL)

    Time frame: Out to 14 hours

  4. Specific Blood Indicators 2

    Change in blood Interleukin-6 (pg/mL)

    Time frame: Out to 14 hours

  5. Specific Blood Indicators 3

    Change in blood C-reactive protein (CRP) (mg/L)

    Time frame: Out to 14 hours

  6. Specific Blood Indicators 4

    Change in blood Lactate Dehydrogenase (LDH) (U/L)

    Time frame: Out to 14 hours

  7. Specific Blood Indicators 5

    Change in blood D-dimer (mcg/L\*FEU2)

    Time frame: Out to 14 hours

  8. Specific Blood Indicators 6

    Change in blood White Blood Cell (WBC) count (%)

    Time frame: Out to 14 hours

  9. Specific Blood Indicators 7

    Change in blood Neutrophil count (%)

    Time frame: Out to 14 hours

  10. Specific Blood Indicators 8

    Change in blood lymphocyte count (%).

    Time frame: Out to 14 hours

  11. Hospital Acquired Infections (HAI) /Sepsis

    Change in the duration of days of diagnosed HAI/ Sepsis infections

    Time frame: 30 and 60 days

  12. Composite Recovery

    Duration without Respiratory Replacement Therapy (RRT), ventilator, and time to discharge

    Time frame: Up to 30 days

  13. Composite Survival

    Survival without Respiratory Replacement Therapy (RRT), ventilator, or time to Long Term Care (LTC)

    Time frame: 30 and 60 days

  14. Composite Non-Recovery

    Survival with Respiratory Replacement Therapy (RRT), ventilator or in Long Term Care (LTC)

    Time frame: Up to 60 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2020; primary completion for Nov 2020, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2020
First posted
Sep 3, 2020
StartEst.
Sep 15, 2020
Primary completionEst.
Nov 15, 2020
CompletionEst.
Jan 15, 2021
Last update
Dec 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04537975
Lead sponsor
SeaStar Medical
Responsible party
Sponsor
First posted
Sep 3, 2020
Start date
Sep 15, 2020 (estimated)
Primary completion
Nov 15, 2020 (estimated)
Completion
Jan 15, 2021 (estimated)
Last update
Dec 14, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion